UTI Mutual Fund decreased its stake in Eris Lifesciences from 1.92% to 1.58% by selling 4,67,922 shares. The value of shares sold is ₹68.09 Cr at ₹1455.40 apiece.
A pharmaceutical manufacturer and marketer, ERIS Lifesciences produces branded and generic drugs across multiple therapeutic areas including cardiovascular, gastroenterology, and anti-infective segments. The company operates manufacturing facilities and distributes medications through established distribution networks to serve both domestic and international markets. It focuses on developing and delivering cost-effective pharmaceutical formulations for diverse patient populations.
India's oldest and most storied asset manager, founded in 1963 as the Unit Trust of India under an Act of Parliament. Now manages over Rs 3.5 lakh crore with backing from four public sector institutions: LIC, SBI, Bank of Baroda, and Punjab National Bank. CIO Vetri Subramaniam is a long-term compounder with a consistent quality tilt and clear articulation of process.
